Sirturo bedaquiline regulatory update

On Dec. 28, 2012, FDA granted accelerated approval to an NDA from Johnson & Johnson for Sirturo bedaquiline to treat adults with multi-drug resistant pulmonary tuberculosis (TB) as part of